Episode Details

It's Infrastructure Week and H.R. 3, a far-reaching piece of legislation which contains a series of drug-pricing reforms, is back.

At the end of 2019, the House of Representatives passed H.R. 3 but partisan disagreements prevented the bill from becoming law. Now, elements of H.R. 3 are back on the table as the Biden administration prepares its $2 trillion infrastructure and jobs package.

Washington University's Rachel Sachs joins Health Affairs' Chris Fleming to break down H.R. 3's three main parts and highlight what they mean for the federal budget, pharmaceutical companies, and consumers.

Related Links:

• Prescription Drug Legislation In Congress: An Update (Health Affairs Blog)
• Rachel Sachs' Health Affairs Articles
• Prescription Drug Policy: The Year In Review, And The Year Ahead (Health Affairs Blog)
• Administration Finalizes Most-Favored Nation Drug Pricing Rules At The Last Minute (Health Affairs Blog)
• Democrats Gear Up For Major Push To Lower Drug Prices (The Hill)

Subscribe: RSS | Apple Podcasts | Spotify | Castro | Stitcher | Deezer | Overcast